United Therapeutics announced an expanded partnership with MannKind, covering a new development product.
4 reports, 3 independent
Updated Aug 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
United Therapeutics announced an expanded partnership with MannKind, covering a new development product.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Partnership expansion and new product development for United Therapeutics.1 source
Expanded collaboration between MannKind and United Therapeutics to develop a second inhaled therapy following FDA approval.1 source
Keep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States
Coverage
Newest first; wire copies grouped- dailypolitical.com
- Simply Wall St.Why MannKind (MNKD) Is Up 11.7% After Expanding Technosphere Partnership With United Therapeutics On August 24, 2025, United Therapeutics announced an amendment to its license and collaboration agree
- Simply Wall St.Should the Expanded Technosphere Partnership With MannKind Shape United Therapeutics’ (UTHR) Investment Outlook? On August 24, 2025, MannKind Corporation announced an amendment to its global license
- GlobeNewswireMannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmo